Tagged with Asia

Korea With the bioPROTAC platform, we can, in principle, degrade essentially any problematic protein Jaehyun Choi, Co-CEO of Genexine, outlines the company’s transition from its established hyFc platform towards bioPROTAC, a novel protein degradation technology. He discusses GX-BP1, partnerships, regulatory challenges in Asia, and Genexine’s strategy of validating the platform through…

Japan Patients in Japan deserve the same access to innovative treatments that patients in other markets have. Accelerating that access is what drives us Noriyuki Takai, CEO of EPS Corporation, outlines the CRO’s mission to help address Japan’s drug lag and drug loss by supporting faster access to innovative medicines. He…

China As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful data quickly. In this context, Harvest Integrated Research Organization has been expanding its international footprint while positioning itself as a…

Asia-Pacific Translating scientific breakthroughs into products that genuinely impact patients is more challenging than it has ever been. Only ten percent of drugs that enter clinical trials ever make it all the way to patients, meaning that much of the USD 250 billion spent on pharma R&D every year goes towards…

China The top 20 Chinese pharma companies ranked by 2023 sales, according to the Citelie Scrip Asia 100. CSPC, Fosun, and Shanghai Pharma top the chart, with a host of other less well-known firms now also generating over a billion dollars in annual sales.   Made with Visme Infographic Maker

China With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set to more than double by 2031. While global players like Santen have taken an early lead, a new wave of…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US rights of tocilizumab biosimilar from Biogen, GE Healthcare’s acquisition of Japan’s Nihon Medi-Physics, Wuxi Biologics’ disposal of vaccine facility to…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to Bayer, AbbVie accusing Genmab of ADC trade secret theft on ADC technology used by ProfoundBio, and Singapore’s A*STAR investing in…

Singapore Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their investments there as of late and either expanded existing manufacturing capabilities, or chosen the city-state as the location for a…

Asia A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean biotech getting a 187 million dollar funding boost, why the Australian regulator has rejected Eisai’s Alzheimer’s drug, the activist fund…

Japan Japan was once a global leader in life sciences innovation, introducing about a third of the world’s new drugs in the 1980s, but this positioning slipped following decades of economic stagnation compounded by a conservative regulatory regime. However recent regulatory reforms have brought a more positive outlook and sparked a…

Japan After 12 years at the helm, Takeda CEO Christophe Weber is stepping down, leaving behind a transformed company. Under his leadership, Japan’s biggest drugmaker expanded globally with the $62 billion acquisition of Shire, made waves with its dengue vaccine QDENGA, navigated the loss of exclusivity on its ADHD blockbuster, and…